Compounds > pyrazines
Page last updated: 2024-08-21

pyrazines and Carcinoma, Epidermoid

pyrazines has been researched along with Carcinoma, Epidermoid in 59 studies

Research

Studies (59)

TimeframeStudies, this research(%)All Research%
pre-19902 (3.39)18.7374
1990's4 (6.78)18.2507
2000's23 (38.98)29.6817
2010's25 (42.37)24.3611
2020's5 (8.47)2.80

Authors

AuthorsStudies
Arafiles, JVV; Futaki, S; Hara, Y; Hirose, H; Imanishi, M; Kuriyama, M; Maekawa, M; Masuda, T; Shudou, M1
Castellano, GM; Garbuzenko, OB; Malhotra, J; Minko, T; Pine, SR; Sabaawy, HE; Zeeshan, S1
Chen, J; Fan, J; Wang, Y; Zhan, Q; Zhang, J; Zhang, L; Zhang, W; Zhao, D1
Amaladas, N; Chaudhary, R; Chung, CH; Conejo-Garcia, JR; Hall, GE; Hernandez-Prera, JC; Masannat, J; McCleary-Sharpe, KP; Slebos, RJC; Song, F; Tan, AC; Wang, X; Wu, W1
Bürkel, F; Distel, LV; Faulhaber, EM; Fietkau, R; Hecht, M; Jost, T; Scheper, J; Symank, J1
Chen, K; Chen, W; Jin, J; Li, D; Mao, W; Su, D; Wu, J; Ying, L; Yu, H; Zhang, F; Zhang, N1
Jin, X; Li, XF; Wang, JY; Zhang, X1
Basler, K; Cantù, C; Cecconi, V; Hafner, J; Hausmann, G; Restivo, G; Valenta, T; van den Broek, M; Zimmerli, D1
Chen, KN; Dai, L; Dong, B; Fu, H; Kang, XZ; Liang, Z; Shen, LY; Shi, Q; Xiong, HC; Yan, WP; Yang, YB1
Johnson, DE; Li, C2
Johnson, DE; Kirk, CJ; Zang, Y1
Ali, SM; Chmielecki, J; Miller, VA; Morosini, D; Palmer, GA; Ross, JS; Sharman, JP; Stafl, J; Stephens, PJ1
Ahn, MJ; Arpornwirat, W; Bazhenova, L; Chen, J; Chiappori, AA; Chow, LQ; de Lima, LG; Dechaphunkul, A; Eaton, K; Gadgeel, SM; Juergens, RA; Leighl, NB; Medley, S; Poondru, S; Rizvi, NA; Rudin, CM; Singh, M; Steinberg, J; Sunpaweravong, P1
Beggs, RR; Cooper, TS; Weaver, AN; Yang, ES; Zeng, L1
Grandis, JR; Johnson, DE; Li, C; Li, R1
Allen, CT; Chen, Z; Colunga, A; Frenkel, V; Li, KC; Poff, JA; Traughber, B; Van Waes, C; Wood, BJ; Xie, J1
Allen, C; Arun, P; Chen, Z; Nottingham, L; Saigal, K; Van Waes, C1
Goldberg, SN1
Diehl, JA; Herlyn, M; Klein-Szanto, A; Lioni, M; Noma, K; Rustgi, AK; Smalley, KS; Snyder, A1
Liang, YM; Liu, H; Wang, QW; Wang, T; Zhu, XD1
Ackermann, H; Arnoldner, C; Baghi, M; Bisdas, S; Gstöttner, W; Hambek, M; Knecht, R; May, A; Wagenblast, J1
Arnoldner, C; Baghi, M; Bisdas, S; Gstöttner, W; Hambek, M; Knecht, R; May, A; Wagenblast, J1
Albain, KS; Chansky, K; Crowley, J; Davies, AM; Gandara, DR; Gumerlock, PH; Lara, PN; Vogel, SJ1
Grandis, JR; Johnson, DE; Li, C; Li, R; Patel, NS; Zang, Y1
Grandis, JR; Johnson, DE; Leeman-Neill, RJ; Li, C; Man, DS; Sen, M; Zang, Y1
Aulino, J; Baumann, J; Burkey, B; Chung, CH; Cmelak, AJ; Gilbert, J; Hatakeyama, H; Muldowney, NJ; Murphy, BA; Netterville, J; Parker, J; Shyr, Y; Sinard, R; Slebos, RJ; Yarbrough, WG1
Jones, DR; Liu, Y; Nagji, AS; Taylor, MD; Theodosakis, N1
Akagi, Y; Fujii, T; Kage, M; Kusukawa, J; Miyagi, M; Sayers, TJ; Seki, N; Shirouzu, K; Toh, U; Yamana, H1
Chang, I; Chen, X; Guan, J; Han, D; Kim, J; Wang, CY1
Chang, I; Chen, Z; Kang, M; Song, J; Wang, CY1
Du, Z; Fan, M; Gu, W; Jiao, Y; Kim, JG; Nosrat, CA; Pavicevic, Z; Pfeffer, LM; Rao, SK; Rosebush, M; Samant, S1
Ahsan, A; Arai, Y; Argiris, A; Chen, Z; Cooley-Zgela, T; Duffy, AG; Jang, M; Kannabiran, VR; Kim, SW; Kummar, S; Nyati, MK; Ramanand, SG; Rudy, SF; Simone, NL; Suksta, N; Van Waes, C; Wright, JJ; Yang, X1
Arwert, EN; Driskell, RR; Goldie, SJ; Hoste, E; Mentink, RA; Quist, S; Watt, FM1
Burr, DA; Cai, P; Callaghan, MU; Cruz, PG; Fribley, AM; Jacobs, RR; Kaufman, RJ; Kirchhoff, PD; Larsen, MJ; Larsen, SD; Miller, JR; Narula, N; Neubig, RR; Ron, D; Schultz, PJ; Sherman, DH; Showalter, HD; Tamayo-Castillo, G1
Besse, B; Ducourtieux, M; Khayat, D; Lafontaine, C; Lumbroso, J; Mathiot, C; Pignon, JP; Planchard, D; Soria, JC; Taillade, L; Veillard, AS1
Chen, CC; Chen, KC; Chen, KF; Cheng, AL; Lin, YC1
Argiris, A; Arun, P; Feldman, LE; Forastiere, AA; Gilbert, J; Haigentz, M; Jang, M; Lee, JW; Van Waes, C1
Chan, ET; DeLancey, HM; Freilino, ML; Grandis, JR; Johnson, DE; Kirk, CJ; Li, C; Thomas, SM; Zang, Y1
Bao, Y; Burks, SG; Gillenwater, HH; Jones, DR; Kozower, BD; Moskaluk, CA; Olazagasti, J; Petroni, GR; Philips, J; Rehm, PK1
Yang, X1
Fribley, A; Wang, CY; Zeng, Q1
Adams, J; Camphausen, K; Chang, AA; Chen, Z; Conley, BA; Druzgal, CH; Elsayed, YA; Gius, D; Lebowitz, PF; Mitchell, JB; Morris, JC; Rudy, SF; Sausville, EA; Sunwoo, JB; Van Waes, C1
Brown, RE; Kennedy, TL; Law, A; Lun, M; Pellitteri, PK; Zhang, PL1
Harada, K; Sato, M; Yoshida, H1
Evenchik, B; Fribley, AM; Guan, JY; Hale, TJ; Kaufman, RJ; Park, BK; Soengas, MS; Wang, CY; Zeng, Q; Zhang, H1
McKenna, KE; Morris, TC; Ramadan, KM1
Lorch, JH; Schmoll, HJ; Thomas, TO1
Ara, G; Chen, Z; Duan, J; Friedman, J; Nottingham, L; Van Waes, C1
Birle, DC; Hedley, DW1
Ackermann, H; Baghi, M; Gstöttner, W; Hambek, M; Knecht, R; Strebhardt, K; Wagenblast, J1
Dicker, AP; Kamer, S; Ren, Q1
Cassel, D; Glaser, L; Rothenberg, P; Schlesinger, P1
Katoh, I; Kyushiki, H; Sakamoto, Y; Yoshinaka, Y1
Adachi, M; Bando, T; Harada, K; Kawai, K; Nakai, S; Nakashiro, K; Sato, M; Shirakami, T; Yoshida, H1
Osaki, T; Ueta, E; Yamamoto, T; Yoneda, K1
Chen, SX; Wang, LX; Xing, LL1
Adams, J; Chen, Z; Crowl Bancroft, C; Dong, G; Elliott, P; Sausville, E; Sunwoo, JB; Van Waes, C; Yeh, N1
Czech, MP; Davis, RJ1

Trials

9 trial(s) available for pyrazines and Carcinoma, Epidermoid

ArticleYear
Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations.
    Clinical lung cancer, 2017, Volume: 18, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Pyrazines; Survival Rate

2017
Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2009, Volume: 4, Issue:1

    Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Pyrazines; Survival Rate; Treatment Outcome

2009
Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; NF-kappa B; Pyrazines; Recurrence; Signal Transduction; Survival Analysis; Taxoids; Treatment Outcome

2010
Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Sep-01, Volume: 17, Issue:17

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Combined Modality Therapy; Cytokines; Disease Progression; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Protease Inhibitors; Pyrazines; Radiotherapy, Intensity-Modulated; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Transcription Factors; Treatment Outcome

2011
Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2012, Volume: 76, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Pyrazines; Survival Rate

2012
CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells.
    Oral oncology, 2012, Volume: 48, Issue:7

    Topics: Animals; Antineoplastic Agents; Apoptosis; Autoantigens; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Head and Neck Neoplasms; In Vitro Techniques; Male; Membrane Proteins; Mice; Mice, Nude; Neoplasms, Experimental; Polymerase Chain Reaction; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Pyrazines; RNA, Small Interfering; Signal Transduction

2012
Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of
    Head & neck, 2013, Volume: 35, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Camptothecin; Carcinoma, Squamous Cell; Cytokines; Disease Progression; Female; Head and Neck Neoplasms; Humans; Irinotecan; Male; Middle Aged; NF-kappa B; Pyrazines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome

2013
Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:11

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Follow-Up Studies; Gene Expression Profiling; Histone Deacetylases; Humans; Hydroxamic Acids; Immunoenzyme Techniques; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Prognosis; Proteasome Endopeptidase Complex; Pyrazines; Vorinostat

2012
[Effects of tetramethylpyrazine on platelet functions of advanced cases of lung carcinoma].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 1997, Volume: 17, Issue:9

    Topics: 6-Ketoprostaglandin F1 alpha; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrazines; Thromboxane B2

1997

Other Studies

50 other study(ies) available for pyrazines and Carcinoma, Epidermoid

ArticleYear
Piezo1 activation using Yoda1 inhibits macropinocytosis in A431 human epidermoid carcinoma cells.
    Scientific reports, 2022, 04-15, Volume: 12, Issue:1

    Topics: Biological Transport; Calcium; Carcinoma, Squamous Cell; Cell Line, Tumor; Epidermal Growth Factor; Humans; Ion Channels; Pinocytosis; Pyrazines; Thiadiazoles

2022
Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma.
    Molecular cancer therapeutics, 2022, 09-06, Volume: 21, Issue:9

    Topics: Animals; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; DNA; Humans; Lung; Lung Neoplasms; Mechanistic Target of Rapamycin Complex 1; Mice; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; TOR Serine-Threonine Kinases; Triazoles

2022
Focal adhesion kinase (FAK) inhibitor-defactinib suppresses the malignant progression of human esophageal squamous cell carcinoma (ESCC) cells via effective blockade of PI3K/AKT axis and downstream molecular network.
    Molecular carcinogenesis, 2021, Volume: 60, Issue:2

    Topics: Animals; Benzamides; Carcinoma, Squamous Cell; Cell Line, Tumor; Disease Progression; Esophageal Neoplasms; Female; Focal Adhesion Protein-Tyrosine Kinases; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Ontology; Gene Regulatory Networks; Humans; Kaplan-Meier Estimate; Mice, Inbred BALB C; Mice, Nude; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays

2021
Effects of checkpoint kinase 1 inhibition by prexasertib on the tumor immune microenvironment of head and neck squamous cell carcinoma.
    Molecular carcinogenesis, 2021, Volume: 60, Issue:2

    Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Checkpoint Kinase 1; DNA Damage; Head and Neck Neoplasms; Humans; Male; Mice, Inbred C57BL; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Survival Analysis; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays

2021
Kinase Inhibitors of DNA-PK, ATM and ATR in Combination with Ionizing Radiation Can Increase Tumor Cell Death in HNSCC Cells While Sparing Normal Tissue Cells.
    Genes, 2021, 06-17, Volume: 12, Issue:6

    Topics: Ataxia Telangiectasia Mutated Proteins; Carcinoma, Squamous Cell; Cell Death; Cell Line, Tumor; Cells, Cultured; DNA Repair; DNA-Activated Protein Kinase; Head and Neck Neoplasms; Humans; Isoxazoles; Protein Kinase Inhibitors; Pyrazines; Pyridines; Quinolines; Triazoles; X-Rays

2021
Overcoming Linsitinib intrinsic resistance through inhibition of nuclear factor-κB signaling in esophageal squamous cell carcinoma.
    Cancer medicine, 2017, Volume: 6, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Extracellular Signal-Regulated MAP Kinases; Humans; Imidazoles; Interleukin-6; Interleukin-8; NF-kappa B; Phenylenediamines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pyrazines; RNA, Messenger; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Cells, Cultured

2017
CC-223 inhibits human head and neck squamous cell carcinoma cell growth.
    Biochemical and biophysical research communications, 2018, 02-19, Volume: 496, Issue:4

    Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Head and Neck Neoplasms; Humans; Protein Kinase Inhibitors; Pyrazines; Squamous Cell Carcinoma of Head and Neck; TOR Serine-Threonine Kinases; Treatment Outcome

2018
WNT ligands control initiation and progression of human papillomavirus-driven squamous cell carcinoma.
    Oncogene, 2018, Volume: 37, Issue:27

    Topics: Acyltransferases; Animals; Carcinoma, Squamous Cell; Enzyme Inhibitors; Gene Expression Profiling; Humans; Membrane Proteins; Mice; Neoplastic Stem Cells; Papillomaviridae; Papillomavirus Infections; Pyrazines; Pyridines; Skin Neoplasms; Stem Cell Niche; Wnt Proteins; Wnt Signaling Pathway

2018
The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma.
    Cancer letters, 2018, 09-28, Volume: 432

    Topics: Animals; Antineoplastic Agents; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; Cisplatin; CRISPR-Cas Systems; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Isoxazoles; Mice; Mice, Inbred BALB C; Mice, Nude; Prognosis; Pyrazines; Signal Transduction; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2018
Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest.
    Cell cycle (Georgetown, Tex.), 2013, Mar-15, Volume: 12, Issue:6

    Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Head and Neck Neoplasms; Human papillomavirus 16; Humans; Oncogene Proteins, Viral; Papillomavirus E7 Proteins; Papillomavirus Infections; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Repressor Proteins; RNA Interference; RNA, Messenger; RNA, Small Interfering; Squamous Cell Carcinoma of Head and Neck; Tumor Suppressor Protein p53; Ubiquitination

2013
Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
    Cancer biology & therapy, 2014, Volume: 15, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Head and Neck Neoplasms; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Membrane Proteins; Mitochondrial Proteins; Oligopeptides; Proteasome Inhibitors; Pyrazines; Vorinostat

2014
Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.
    Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:5

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Combined Modality Therapy; Dexamethasone; Disease Progression; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lenalidomide; Male; Mediastinal Neoplasms; Middle Aged; Multiple Myeloma; Mutation, Missense; Neoplasm Proteins; Neoplasms, Second Primary; Osteolysis; Palliative Care; Plasmacytoma; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrazines; Remission Induction; Salvage Therapy; Sulfonamides; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vemurafenib

2014
Combining Chk1/2 Inhibition with Cetuximab and Radiation Enhances
    Molecular cancer therapeutics, 2017, Volume: 16, Issue:4

    Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cetuximab; Checkpoint Kinase 1; Checkpoint Kinase 2; Chemoradiotherapy; Combined Modality Therapy; DNA Damage; Drug Synergism; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Mice; Pyrazines; Pyrazoles; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays

2017
Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells.
    Molecular cancer therapeutics, 2008, Volume: 7, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Head and Neck Neoplasms; Humans; Membrane Proteins; Mitochondrial Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Proteasome Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Up-Regulation

2008
Pulsed high-intensity focused ultrasound enhances apoptosis and growth inhibition of squamous cell carcinoma xenografts with proteasome inhibitor bortezomib.
    Radiology, 2008, Volume: 248, Issue:2

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Combined Modality Therapy; Mice; Pyrazines; Random Allocation; Transplantation, Heterologous; Tumor Cells, Cultured; Ultrasonic Therapy

2008
Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Jul-01, Volume: 14, Issue:13

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Nucleus; DNA; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Models, Biological; NF-kappa B; Phosphorylation; Pyrazines; Recurrence; Signal Transduction; Subcellular Fractions

2008
Can tumor growth be further inhibited by combining drugs such as bortezomib with image-guided interventional oncologic procedures?
    Radiology, 2008, Volume: 248, Issue:2

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Combined Modality Therapy; Mice; Pyrazines; Ultrasonic Therapy

2008
Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway.
    Molecular cancer therapeutics, 2008, Volume: 7, Issue:9

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Caspase 3; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Esophageal Neoplasms; G2 Phase; Histones; Mice; Mice, Inbred NOD; Mitosis; Neovascularization, Pathologic; p38 Mitogen-Activated Protein Kinases; Pyrazines; Remission Induction; Xenograft Model Antitumor Assays

2008
[Proteasome inhibitor bortezomib sensitizes Hep-2 human laryngeal squamous cell carcinoma cells to ionizing radiation in vitro and in vivo].
    Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery, 2008, Volume: 43, Issue:6

    Topics: Animals; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Enzyme Inhibitors; Female; Humans; Laryngeal Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Pyrazines; Radiation Tolerance; Radiation-Sensitizing Agents

2008
Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines.
    Journal of cancer research and clinical oncology, 2009, Volume: 135, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; Cell Survival; Cetuximab; Esophageal Neoplasms; Fibroblasts; Humans; Mouth Neoplasms; Multiple Myeloma; Pyrazines

2009
Effects of combination treatment of bortezomib and dexamethasone in SCCHN cell lines depend on tumor cell specificity.
    Oncology reports, 2008, Volume: 20, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Dexamethasone; Drug Screening Assays, Antitumor; Head and Neck Neoplasms; Humans; Pyrazines

2008
ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway.
    Molecular pharmacology, 2009, Volume: 75, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Biphenyl Compounds; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Drug Synergism; Head and Neck Neoplasms; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Signal Transduction; Sulfonamides

2009
Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death.
    Molecular cancer therapeutics, 2009, Volume: 8, Issue:8

    Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Enzyme Inhibitors; Head and Neck Neoplasms; Humans; Pyrazines; Signal Transduction; STAT3 Transcription Factor; Up-Regulation

2009
Combined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cells.
    The Journal of thoracic and cardiovascular surgery, 2010, Volume: 139, Issue:5

    Topics: Adenocarcinoma; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cadherins; Carcinoma, Squamous Cell; Cell Death; Cell Line, Tumor; Cell Movement; Epithelial Cells; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Mesoderm; Neoplasm Invasiveness; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; RNA, Messenger; Spheroids, Cellular; Time Factors; Transfection; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Up-Regulation; Vorinostat

2010
Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:6

    Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspases; Cell Line, Tumor; Death Domain Receptor Signaling Adaptor Proteins; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Esophageal Neoplasms; Humans; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Up-Regulation

2010
PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:7

    Topics: Acetylation; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Northern; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Caspases; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Head and Neck Neoplasms; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Mice; Mice, Nude; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA Interference; Xenograft Model Antitumor Assays

2010
Characterization of side populations in HNSCC: highly invasive, chemoresistant and abnormal Wnt signaling.
    PloS one, 2010, Jul-06, Volume: 5, Issue:7

    Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; beta Catenin; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Etoposide; Flow Cytometry; Head and Neck Neoplasms; Humans; Neoplasm Proteins; Pyrazines; Signal Transduction; Stem Cells; Wnt Proteins

2010
Pro-inflammatory genes as biomarkers and therapeutic targets in oral squamous cell carcinoma.
    The Journal of biological chemistry, 2010, Oct-15, Volume: 285, Issue:42

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Biomarkers; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cells, Cultured; Dose-Response Relationship, Drug; Gene Expression Profiling; Humans; Inflammation; Interleukin-8; Microarray Analysis; Mouth Neoplasms; NF-kappa B; Pyrazines; RNA, Small Interfering

2010
Upregulation of CD26 expression in epithelial cells and stromal cells during wound-induced skin tumour formation.
    Oncogene, 2012, Feb-23, Volume: 31, Issue:8

    Topics: Animals; Carcinoma, Squamous Cell; Cells, Cultured; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Epidermis; Epithelial Cells; Fibroblasts; Gene Expression; Humans; Interleukin-1alpha; Keratinocytes; Male; MAP Kinase Kinase 1; Mice; Mice, Inbred C57BL; Mice, Transgenic; Papilloma; Pyrazines; Sitagliptin Phosphate; Skin Neoplasms; Stromal Cells; Triazoles; Up-Regulation

2012
Complementary cell-based high-throughput screens identify novel modulators of the unfolded protein response.
    Journal of biomolecular screening, 2011, Volume: 16, Issue:8

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Caspases; Cell Proliferation; CHO Cells; Cricetinae; Drug Evaluation, Preclinical; eIF-2 Kinase; Eukaryotic Initiation Factor-2; Genes, Reporter; High-Throughput Screening Assays; Humans; Luciferases; Mouth Neoplasms; Mycotoxins; Pyrazines; Signal Transduction; Transcription Factor CHOP; Transduction, Genetic; Unfolded Protein Response

2011
Bortezomib induces autophagy in head and neck squamous cell carcinoma cells via JNK activation.
    Cancer letters, 2012, Jan-01, Volume: 314, Issue:1

    Topics: Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Enzyme Activation; Head and Neck Neoplasms; Humans; JNK Mitogen-Activated Protein Kinases; Phosphorylation; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Squamous Cell Carcinoma of Head and Neck

2012
The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4.
    Autophagy, 2012, Volume: 8, Issue:12

    Topics: Activating Transcription Factor 4; Autophagy; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Head and Neck Neoplasms; Humans; Models, Biological; Oligopeptides; Proteasome Inhibitors; Pyrazines; Squamous Cell Carcinoma of Head and Neck; Unfolded Protein Response

2012
Proteasome inhibitor bortezomi-induced the apoptosis of laryngeal squamous cell carcinoma Hep-2 cell line via disrupting redox equilibrium.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2012, Volume: 66, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Caspase 3; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Humans; Laryngeal Neoplasms; Membrane Potential, Mitochondrial; Oxidation-Reduction; Oxidative Stress; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species

2012
Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.
    Molecular and cellular biology, 2004, Volume: 24, Issue:22

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Caspases; Cell Line, Tumor; Endoplasmic Reticulum; Gene Expression Profiling; Head and Neck Neoplasms; Humans; NF-kappa B; Oligonucleotide Array Sequence Analysis; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species; Signal Transduction

2004
Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma.
    International journal of radiation oncology, biology, physics, 2005, Dec-01, Volume: 63, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cytokines; Female; Gene Expression; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mouth Mucosa; Neoplasm Recurrence, Local; NF-kappa B; Protease Inhibitors; Pyrazines; Stomatitis; Transcription Factor RelA

2005
Nuclear factor-kappaB pathway as a therapeutic target in head and neck squamous cell carcinoma: pharmaceutical and molecular validation in human cell lines using Velcade and siRNA/NF-kappaB.
    Annals of clinical and laboratory science, 2005,Summer, Volume: 35, Issue:3

    Topics: Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Dose-Response Relationship, Drug; Head and Neck Neoplasms; Humans; NF-kappa B; Pyrazines; RNA, Small Interfering; Transfection

2005
Vesnarinone inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing the expression of vascular endothelial growth factor and interleukin-8.
    International journal of oncology, 2005, Volume: 27, Issue:6

    Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Interleukin-8; Mice; Mice, Inbred BALB C; Mice, Nude; Mouth Neoplasms; Neovascularization, Pathologic; NF-kappa B; Protein Binding; Pyrazines; Quinolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2005
Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa.
    The Journal of biological chemistry, 2006, Oct-20, Volume: 281, Issue:42

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cisplatin; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Eukaryotic Initiation Factor-2; Humans; Mice; Phosphorylation; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines

2006
Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma.
    The Lancet. Oncology, 2006, Volume: 7, Issue:11

    Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Clarithromycin; Dexamethasone; Diphosphonates; Glomerulonephritis; Humans; Idarubicin; Imidazoles; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Nephrotic Syndrome; Pamidronate; Protein Synthesis Inhibitors; Pyrazines; Skin Neoplasms; Thalidomide; Zoledronic Acid

2006
Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer.
    Cancer research, 2007, Jan-15, Volume: 67, Issue:2

    Topics: Adherens Junctions; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Cell Movement; Desmoglein 2; Desmoplakins; Desmosomal Cadherins; Drug Synergism; ErbB Receptors; Focal Adhesion Kinase 1; Humans; Pyrazines; Tongue Neoplasms

2007
Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
    Molecular cancer therapeutics, 2007, Volume: 6, Issue:1

    Topics: Acetylation; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; bcl-X Protein; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; DNA, Neoplasm; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Head and Neck Neoplasms; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Inhibitor of Apoptosis Proteins; Mice; Mice, SCID; NF-kappa B p50 Subunit; Proteasome Inhibitors; Protein Binding; Pyrazines; RNA, Small Interfering; Sulfonamides; Transcription Factor RelA; Xenograft Model Antitumor Assays

2007
Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors.
    Cancer research, 2007, Feb-15, Volume: 67, Issue:4

    Topics: Antigens, Neoplasm; Antineoplastic Agents; Boronic Acids; Bortezomib; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Squamous Cell; Caspase 3; Cell Hypoxia; Cell Line, Tumor; Cell Nucleus; Colonic Neoplasms; E1A-Associated p300 Protein; Enzyme Activation; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Leupeptins; Male; Prostatic Neoplasms; Protease Inhibitors; Protein Binding; Pyrazines; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2007
Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines.
    Journal of cancer research and clinical oncology, 2008, Volume: 134, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Head and Neck Neoplasms; Humans; Pyrazines; Taxoids

2008
Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341).
    Archives of gynecology and obstetrics, 2009, Volume: 279, Issue:1

    Topics: Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Survival; Female; HeLa Cells; Humans; NF-kappa B; Protease Inhibitors; Pyrazines; Radiation Tolerance; Radiation-Sensitizing Agents; Uterine Cervical Neoplasms

2009
Epidermal growth factor stimulates amiloride-sensitive 22Na+ uptake in A431 cells. Evidence for Na+/H+ exchange.
    The Journal of biological chemistry, 1983, Apr-25, Volume: 258, Issue:8

    Topics: Amiloride; Calcium; Carcinoma, Squamous Cell; Carrier Proteins; Cell Line; Dose-Response Relationship, Drug; Epidermal Growth Factor; Humans; Ouabain; Pyrazines; Sodium; Sodium-Hydrogen Exchangers

1983
Alterations of the cytoskeletal organization in tumor cell lines by a cardiotonic drug, vesnarinone, through protein tyrosine phosphorylation.
    Experimental cell research, 1995, Volume: 219, Issue:1

    Topics: 3T3 Cells; Adenosine Triphosphate; Animals; Carcinoma, Squamous Cell; Cardiotonic Agents; Catechols; Cell Communication; Cell Line; Cell Line, Transformed; Cytoskeleton; Electrophoresis, Polyacrylamide Gel; ErbB Receptors; Genes, src; Humans; Immunoblotting; Lung Neoplasms; Mice; Nitriles; Phosphoproteins; Phosphotyrosine; Protein-Tyrosine Kinases; Pyrazines; Quinolines; Tubulin; Tumor Cells, Cultured; Tyrosine; Tyrphostins; Vimentin

1995
Characteristics of antitumor activity of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]- 2(1H)-quinolinone (vesnarinone) against a human adenoid squamous carcinoma-forming cell line grown in athymic nude mice.
    Cancer letters, 1995, May-04, Volume: 91, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Differentiation; DNA Damage; Drug Evaluation, Preclinical; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Pyrazines; Quinolines; Transplantation, Heterologous; Tumor Cells, Cultured

1995
Induction of cyclin-dependent kinase inhibitor p21 in vesnarinone-induced differentiation of squamous cell carcinoma cells.
    Cancer letters, 1998, Nov-13, Volume: 133, Issue:1

    Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Differentiation; Cyclin E; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; G1 Phase; Humans; Mouth Neoplasms; Phosphorylation; Promoter Regions, Genetic; Pyrazines; Quinolines; Retinoblastoma Protein; RNA, Messenger; Transforming Growth Factor beta; Tumor Cells, Cultured; Tumor Suppressor Protein p53

1998
Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:5

    Topics: Animals; Antineoplastic Agents; Blood Vessels; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Cysteine Endopeptidases; Cytokines; Disease Models, Animal; Gene Expression; Humans; Mice; Mice, Inbred BALB C; Mice, SCID; Multienzyme Complexes; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; NF-kappa B; Proteasome Endopeptidase Complex; Pyrazines; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2001
Amiloride directly inhibits growth factor receptor tyrosine kinase activity.
    The Journal of biological chemistry, 1985, Feb-25, Volume: 260, Issue:4

    Topics: Adenosine Triphosphate; Amiloride; Animals; Binding, Competitive; Carcinoma, Squamous Cell; Cell Line; Cell Membrane; Epidermal Growth Factor; ErbB Receptors; Histones; Humans; Kinetics; Mice; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Receptor, Insulin; Receptors, Cell Surface; Receptors, Platelet-Derived Growth Factor; Sodium

1985